ArticleInternational ophthalmology2026
Results of adjunctive homogenate amniotic membrane eye drops in the management of refractory ocular surface disease with dry eye manifestations.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate clinical outcomes of adjunctive treatment with homogenate human amniotic membrane eye drops (AMED) in patients with refractory ocular surface disease with dry eye (DE) manifestations.
methodsWe retrospectively reviewed patients' medical records, ocular surface images, and instrumental data related to Schirmer I test, Oxford and Efron grading, non-invasive tear break-up time, Ocular Surface Disease Index (OSDI), adverse events, and symptom recurrence after discontinuation. All patients were assessed for safety while the efficacy analysis included patients who completed 2-month uninterrupted AMED treatment, without modification of topical or systemic therapy in the previous two months or during the treatment period.
resultsA total of 160 patients were exposed to AMED. Twenty-three (14.4%) patients discontinued treatment and 25 (15.6%) showed adverse events. 112 (70%) patients [mean (SD) age 57 (16) years], 73.0% female, were included in the efficacy analysis. We observed improvement in corneal Oxford grading in graft-versus-host disease (GVHD) and limbal stem cell deficiency (LSCD) patients (P < 0.001 and P = 0.02, respectively) and conjunctival Oxford grading in GVHD, LSCD, Sjögren's syndrome (SS) and non-Sjögren's dry eye (NSDE) (P < 0.001); decreasing in Efron score in GVHD and SS (P < 0.001 and P = 0.03, respectively). Tear film stability improved across almost all groups and OSDI showed clinically modest changes. Symptoms recurrence was reported in 86.9% of patients within one month after AMED discontinuation without adverse events reported during 2-month continuous treatment.
conclusionsAdjunctive AMED treatment was associated with objective improvements of ocular surface, with limited effects on symptoms, likely reflecting the multifactorial nature of DE manifestations across clinically and pathophysiological distinct entities.
Indexed as
Identifiers
42274910What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.